Incremental Diagnostic Value of Tau-PET with [18F]RO948 Vs Amyloid-PET in Patients with
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:
• Written Inform Consent to participating.
• 50 to 85 years of age
• a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments)
• availability of MRI within 6 months before screening
• prescription of a diagnostic amyloid PET
• Willing and able to comply with the requirements of the study, as judged by the investigator.
Locations
Other Locations
Switzerland
Geneva University Hospital
RECRUITING
Geneva
Centre Medical Universitaire Vaudois
NOT_YET_RECRUITING
Lausanne
Contact Information
Primary
Valentina Garibotto, MD
valentina.garibotto@hug.ch
+41223727252
Time Frame
Start Date: 2024-12-09
Estimated Completion Date: 2027-08-30
Participants
Target number of participants: 120
Treatments
Experimental: Amyloid-PET and then Tau-PET
The participant will have the Amyloid-PET (standard of care) and then Tau-PET (experimental)
Experimental: Tau-PET and then Amyloid-PET
The participant will have the Tau-PET (experimental) and then the Amyloid-PET (standard of care)
Related Therapeutic Areas
Sponsors
Collaborators: Centre Hospitalier Universitaire Vaudois
Leads: University Hospital, Geneva